RU2011132212A - Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция - Google Patents
Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция Download PDFInfo
- Publication number
- RU2011132212A RU2011132212A RU2011132212/10A RU2011132212A RU2011132212A RU 2011132212 A RU2011132212 A RU 2011132212A RU 2011132212/10 A RU2011132212/10 A RU 2011132212/10A RU 2011132212 A RU2011132212 A RU 2011132212A RU 2011132212 A RU2011132212 A RU 2011132212A
- Authority
- RU
- Russia
- Prior art keywords
- arg
- seq
- ser
- leu
- asp gln
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 7
- 108010075704 HLA-A Antigens Proteins 0.000 title claims 5
- 102000011786 HLA-A Antigens Human genes 0.000 title 1
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 claims abstract 28
- VAIZFHMTBFYJIA-ACZMJKKPSA-N Ser-Asp-Gln Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O VAIZFHMTBFYJIA-ACZMJKKPSA-N 0.000 claims abstract 28
- LIEIYPBMQJLASB-SRVKXCTJSA-N His-Gln-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CN=CN1 LIEIYPBMQJLASB-SRVKXCTJSA-N 0.000 claims abstract 15
- FHKZHRMERJUXRJ-DCAQKATOSA-N His-Ser-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 FHKZHRMERJUXRJ-DCAQKATOSA-N 0.000 claims abstract 13
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 claims abstract 13
- ADJWHHZETYAAAX-SRVKXCTJSA-N Leu-Ser-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ADJWHHZETYAAAX-SRVKXCTJSA-N 0.000 claims abstract 13
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 claims abstract 13
- 150000001413 amino acids Chemical group 0.000 claims abstract 13
- 108010027345 wheylin-1 peptide Proteins 0.000 claims abstract 13
- LECIJRIRMVOFMH-ULQDDVLXSA-N Lys-Pro-Phe Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LECIJRIRMVOFMH-ULQDDVLXSA-N 0.000 claims abstract 11
- BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 claims abstract 11
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 claims abstract 11
- 108010051242 phenylalanylserine Proteins 0.000 claims abstract 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract 9
- 201000011510 cancer Diseases 0.000 claims abstract 9
- 108700028369 Alleles Proteins 0.000 claims abstract 8
- 102000040430 polynucleotide Human genes 0.000 claims abstract 8
- 108091033319 polynucleotide Proteins 0.000 claims abstract 8
- 239000002157 polynucleotide Substances 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 3
- 102100022748 Wilms tumor protein Human genes 0.000 claims 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 6
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 abstract 1
- GFHXZNVJIKMAGO-IHRRRGAJSA-N Pro-Phe-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O GFHXZNVJIKMAGO-IHRRRGAJSA-N 0.000 abstract 1
- QKQDTEYDEIJPNK-GUBZILKMSA-N Ser-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO QKQDTEYDEIJPNK-GUBZILKMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
1. Фармацевтическая композиция для лечения или профилактики рака у субъекта, несущего аллель HLA-A3303, содержащая пептид, включающий аминокислотную последовательность, выбранную из:Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) иThr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5).2. Фармацевтическая композиция по п.1, где пептид представляет собой Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4).3. Применение пептида, содержащего аминокислотную последовательность, выбранную из:Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) иThr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5),для изготовления лекарственного средства для лечения или профилактики рака у субъекта, несущего аллель HLA-A3303.4. Фармацевтическая композиция для лечения или профилактики рака у субъекта, несущего аллель HLA-A3303, содержащая полинуклеотид, кодирующий пептид, содержащий аминокислотную последовательность, выбранную из:Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) иThr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5),или вектор, содержащий указанный полинуклеотид.5. Применение полинуклеотида, кодирующего пептид, содержащий аминокислотную последовательность, выбранную из:Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) иThr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5),или вектора, содержащего указанный полинуклеотид для изготовления лекарственного средства для лечения или профилактики рака у субъекта, несущего аллель HLA-A3303.6. WT1-специфичные ЦТЛ, индуцируемые пептидом, содержащим аминокислотную последовательность, выбранную из:Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) иThr S
Claims (10)
1. Фармацевтическая композиция для лечения или профилактики рака у субъекта, несущего аллель HLA-A*3303, содержащая пептид, включающий аминокислотную последовательность, выбранную из:
Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),
Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),
Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) и
Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5).
2. Фармацевтическая композиция по п.1, где пептид представляет собой Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4).
3. Применение пептида, содержащего аминокислотную последовательность, выбранную из:
Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),
Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),
Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) и
Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5),
для изготовления лекарственного средства для лечения или профилактики рака у субъекта, несущего аллель HLA-A*3303.
4. Фармацевтическая композиция для лечения или профилактики рака у субъекта, несущего аллель HLA-A*3303, содержащая полинуклеотид, кодирующий пептид, содержащий аминокислотную последовательность, выбранную из:
Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),
Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),
Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) и
Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5),
или вектор, содержащий указанный полинуклеотид.
5. Применение полинуклеотида, кодирующего пептид, содержащий аминокислотную последовательность, выбранную из:
Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),
Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),
Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) и
Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5),
или вектора, содержащего указанный полинуклеотид для изготовления лекарственного средства для лечения или профилактики рака у субъекта, несущего аллель HLA-A*3303.
6. WT1-специфичные ЦТЛ, индуцируемые пептидом, содержащим аминокислотную последовательность, выбранную из:
Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),
Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),
Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) и
Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5).
7. Способ индукции WT1-специфичных ЦТЛ, включающий в себя культивирование мононуклеарных клеток периферической крови в присутствии пептида, содержащего аминокислотную последовательность, выбранную из:
Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),
Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),
Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) и
Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5),
для индукции WT1-специфичных ЦТЛ из мононуклеарных клеток периферической крови.
8. Антиген-представляющие клетки, представляющие пептид WT1, которые индуцируются пептидом, содержащим аминокислотную последовательность, выбранную из:
Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),
Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),
Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) и
Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5).
9. Способ индукции антиген-представляющих клеток, представляющих пептид WT1, включающий культивирование незрелых антиген-представляющих клеток в присутствии пептида, содержащего аминокислотную последовательность, выбранную из:
Leu Ser His Leu Gln Met His Ser Arg (SEQ ID No: 2),
Phe Ser Arg Ser Asp Gln Leu Lys Arg (SEQ ID No: 3),
Ser Asp Gln Leu Lys Arg His Gln Arg (SEQ ID No: 4) и
Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID No: 5),
для индукции антиген-представляющих клеток, представляющих пептид WT1, из незрелых антиген-представляющих клеток.
10. Способ диагностики рака, включающий применение ЦТЛ по п.6 или антиген-представляющих клеток по п.8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006045287 | 2006-02-22 | ||
| JP2006-045287 | 2006-02-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008137635/10A Division RU2435782C2 (ru) | 2006-02-22 | 2007-02-21 | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011132212A true RU2011132212A (ru) | 2013-02-10 |
Family
ID=38437397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008137635/10A RU2435782C2 (ru) | 2006-02-22 | 2007-02-21 | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция |
| RU2011132212/10A RU2011132212A (ru) | 2006-02-22 | 2011-07-29 | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008137635/10A RU2435782C2 (ru) | 2006-02-22 | 2007-02-21 | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8759483B2 (ru) |
| EP (3) | EP2385117B1 (ru) |
| JP (1) | JP5393144B2 (ru) |
| KR (1) | KR101391561B1 (ru) |
| CN (3) | CN102702319B (ru) |
| AU (1) | AU2007218649B2 (ru) |
| BR (1) | BRPI0708125A2 (ru) |
| CA (4) | CA2638122A1 (ru) |
| CY (1) | CY1113117T1 (ru) |
| DK (2) | DK2518149T3 (ru) |
| ES (3) | ES2558330T3 (ru) |
| HK (1) | HK1125968A1 (ru) |
| IL (4) | IL193026A (ru) |
| MX (1) | MX2008010842A (ru) |
| MY (1) | MY149527A (ru) |
| NO (1) | NO20084008L (ru) |
| PH (1) | PH12012502372B1 (ru) |
| PL (1) | PL1988163T3 (ru) |
| PT (1) | PT1988163E (ru) |
| RU (2) | RU2435782C2 (ru) |
| SI (1) | SI1988163T1 (ru) |
| WO (1) | WO2007097358A1 (ru) |
| ZA (1) | ZA200806542B (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100513563C (zh) | 2003-11-05 | 2009-07-15 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
| JP2009511637A (ja) | 2005-10-17 | 2009-03-19 | スローン−ケターリング インスティチュート フォー キャンサー リサーチ | Ｈｌａクラスｉｉ結合ｗｔ１ペプチド及びその組成物、並びにその作成方法 |
| DK2518149T3 (en) | 2006-02-22 | 2016-01-11 | Int Inst Cancer Immunology Inc | HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| CA2645766A1 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
| RU2680539C2 (ru) | 2007-02-27 | 2019-02-22 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. | Способ активации хелперных т-клеток и композиция для применения в данном способе |
| US10654892B2 (en) | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
| SG193956A1 (en) | 2011-04-01 | 2013-11-29 | Sloan Kettering Inst Cancer | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
| KR20140083986A (ko) | 2011-09-14 | 2014-07-04 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 항wt1 항체의 측정 방법 |
| CN108676069A (zh) | 2012-01-13 | 2018-10-19 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽及其使用方法 |
| CN104797711B (zh) | 2012-09-12 | 2018-09-21 | 株式会社癌免疫研究所 | 抗原特异性辅助性t细胞受体基因 |
| US10220082B2 (en) | 2012-12-13 | 2019-03-05 | Inovio Pharmaceuticals, Inc. | WT1 vaccine |
| US9833493B2 (en) | 2012-12-17 | 2017-12-05 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
| CN110078813B (zh) | 2013-01-15 | 2023-03-28 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽和其使用方法 |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| RU2685933C2 (ru) | 2013-02-05 | 2019-04-23 | Нитто Денко Корпорейшн | Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения |
| CA2840954A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for transdermal or mucosal administration |
| KR20140100422A (ko) | 2013-02-05 | 2014-08-14 | 닛토덴코 가부시키가이샤 | 백신 조성물 |
| CN103961307B (zh) | 2013-02-05 | 2019-11-29 | 日东电工株式会社 | 经皮给予用wt1肽癌症疫苗组合物 |
| KR102045029B1 (ko) | 2013-02-05 | 2019-11-14 | 닛토덴코 가부시키가이샤 | 점막 투여용 ｗｔ1 펩티드 암 백신 조성물 |
| JP6440360B2 (ja) | 2013-02-05 | 2018-12-19 | 日東電工株式会社 | 経皮投与用ワクチン組成物 |
| EP2762156A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Tape preparation of WT1 peptide cancer vaccine for transdermal administration |
| CA2840974A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for mucosal administration |
| WO2016093326A1 (ja) | 2014-12-11 | 2016-06-16 | 株式会社癌免疫研究所 | 血管新生病の免疫療法 |
| CN107427581A (zh) | 2014-12-25 | 2017-12-01 | 株式会社癌免疫研究所 | T细胞群的改变方法 |
| EP3271024A4 (en) | 2015-03-20 | 2018-12-05 | The Trustees of the University of Pennsylvania | Isg15 and its use as an adjuvant |
| JP6994201B2 (ja) | 2016-11-09 | 2022-02-21 | 国立大学法人大阪大学 | Ｔ細胞集団の改変方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69033127T2 (de) * | 1989-11-13 | 1999-10-14 | Massachusetts Institute Of Technology | Lokalisation und charakterisierung des wilms-tumor-gens |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6344436B1 (en) * | 1996-01-08 | 2002-02-05 | Baylor College Of Medicine | Lipophilic peptides for macromolecule delivery |
| US6270777B1 (en) * | 1996-12-20 | 2001-08-07 | University Technologies International Inc. | Conserved metalloprotease epitopes |
| GB9805877D0 (en) * | 1998-03-20 | 1998-05-13 | Imp Cancer Res Tech | Cancer |
| US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US20030039635A1 (en) | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| MY139226A (en) * | 1998-09-30 | 2009-08-28 | Corixa Corp | Compositions and methods for wt1 specific immunotherapy |
| US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| WO2001025273A2 (en) * | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
| US6797695B1 (en) * | 1999-10-22 | 2004-09-28 | Kyoto University | Human FGF-20 gene and gene expression products |
| WO2002014361A2 (en) * | 2000-08-17 | 2002-02-21 | Agensys, Inc. | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER |
| EP1371664B1 (en) * | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti modified peptide |
| US20040197892A1 (en) * | 2001-04-04 | 2004-10-07 | Michael Moore | Composition binding polypeptides |
| SI20875A (sl) * | 2001-04-25 | 2002-10-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristalna oblika omeprazola |
| ATE466084T1 (de) | 2002-06-12 | 2010-05-15 | Int Inst Cancer Immunology Inc | Hla-a24-restringiertes krebsantigenpeptid |
| WO2004024175A1 (ja) * | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| JP4498274B2 (ja) | 2003-01-15 | 2010-07-07 | 株式会社癌免疫研究所 | 二量体化ペプチド |
| CA2514058C (en) * | 2003-01-24 | 2014-05-13 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer |
| US6980709B2 (en) | 2003-06-20 | 2005-12-27 | Northrop Grumman Corporation | Polymeric material with voids that compress to allow the polymeric material to absorb applied force and decrease reaction force to one or more sensor fibers |
| EP2186896B1 (en) * | 2004-03-31 | 2015-11-04 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptides derived from WT1 |
| DK2518149T3 (en) | 2006-02-22 | 2016-01-11 | Int Inst Cancer Immunology Inc | HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
-
2007
- 2007-02-21 DK DK12174393.4T patent/DK2518149T3/en active
- 2007-02-21 CN CN201210158264.0A patent/CN102702319B/zh not_active Expired - Fee Related
- 2007-02-21 PL PL07714676T patent/PL1988163T3/pl unknown
- 2007-02-21 PT PT07714676T patent/PT1988163E/pt unknown
- 2007-02-21 WO PCT/JP2007/053176 patent/WO2007097358A1/ja active Application Filing
- 2007-02-21 ES ES12174393.4T patent/ES2558330T3/es active Active
- 2007-02-21 ES ES07714676T patent/ES2387685T3/es active Active
- 2007-02-21 CA CA002638122A patent/CA2638122A1/en not_active Abandoned
- 2007-02-21 DK DK07714676.9T patent/DK1988163T3/da active
- 2007-02-21 US US12/280,268 patent/US8759483B2/en not_active Expired - Fee Related
- 2007-02-21 JP JP2008501735A patent/JP5393144B2/ja active Active
- 2007-02-21 CN CN2007800059709A patent/CN101384716B/zh active Active
- 2007-02-21 CA CA2886551A patent/CA2886551A1/en not_active Abandoned
- 2007-02-21 EP EP11161436.8A patent/EP2385117B1/en not_active Not-in-force
- 2007-02-21 CA CA2886615A patent/CA2886615A1/en not_active Abandoned
- 2007-02-21 MX MX2008010842A patent/MX2008010842A/es active IP Right Grant
- 2007-02-21 CA CA2886552A patent/CA2886552A1/en not_active Abandoned
- 2007-02-21 SI SI200730972T patent/SI1988163T1/sl unknown
- 2007-02-21 BR BRPI0708125-1A patent/BRPI0708125A2/pt not_active IP Right Cessation
- 2007-02-21 EP EP07714676A patent/EP1988163B1/en not_active Not-in-force
- 2007-02-21 MY MYPI20082861A patent/MY149527A/en unknown
- 2007-02-21 CN CN2011101569270A patent/CN102250211A/zh active Pending
- 2007-02-21 RU RU2008137635/10A patent/RU2435782C2/ru not_active IP Right Cessation
- 2007-02-21 AU AU2007218649A patent/AU2007218649B2/en not_active Ceased
- 2007-02-21 ES ES11161436.8T patent/ES2587980T3/es active Active
- 2007-02-21 EP EP12174393.4A patent/EP2518149B1/en not_active Not-in-force
-
2008
- 2008-07-24 IL IL193026A patent/IL193026A/en not_active IP Right Cessation
- 2008-07-28 ZA ZA200806542A patent/ZA200806542B/xx unknown
- 2008-08-21 KR KR1020087020447A patent/KR101391561B1/ko active IP Right Grant
- 2008-09-19 NO NO20084008A patent/NO20084008L/no not_active Application Discontinuation
-
2009
- 2009-04-28 HK HK09103920.0A patent/HK1125968A1/xx unknown
-
2011
- 2011-07-29 RU RU2011132212/10A patent/RU2011132212A/ru not_active Application Discontinuation
-
2012
- 2012-02-16 IL IL218172A patent/IL218172A0/en unknown
- 2012-03-02 US US13/411,453 patent/US8778350B2/en not_active Expired - Fee Related
- 2012-09-18 CY CY20121100848T patent/CY1113117T1/el unknown
- 2012-11-29 PH PH12012502372A patent/PH12012502372B1/en unknown
-
2013
- 2013-12-31 US US14/145,144 patent/US8968745B2/en not_active Expired - Fee Related
- 2013-12-31 US US14/145,363 patent/US8945578B2/en not_active Expired - Fee Related
- 2013-12-31 US US14/145,221 patent/US8933038B2/en not_active Expired - Fee Related
-
2014
- 2014-05-01 IL IL232409A patent/IL232409A0/en unknown
- 2014-05-01 IL IL232408A patent/IL232408A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011132212A (ru) | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция | |
| CN105377291B (zh) | 免疫原性wt-1肽和其使用方法 | |
| TWI599367B (zh) | Ｈｌａ-ａ*１１０１限制性ｗｔ１胜肽之用途 | |
| RU2013141923A (ru) | Вакцинная композиция против злокачественной опухоли | |
| CN107011426A (zh) | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 | |
| KR101561175B1 (ko) | Ｃｄｈ３ 펩티드 및 이를 포함하는 의약제 | |
| NZ599161A (en) | Method for activation of helper t cell and composition for use in the method | |
| RU2013112616A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| JP6898225B2 (ja) | Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 | |
| CN101495501A (zh) | 用于免疫治疗的hla-b7隐性表位的鉴定、优化与应用 | |
| Elvitigala et al. | First report on the gastropod proapoptotic AIF3 counterpart from disk abalone (Haliotis discus discus) deciphering its transcriptional modulation by induced pathogenic stress | |
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| CN108135973A (zh) | 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途 | |
| FR2900407B1 (fr) | Nouveaux polypeptides induisant des cellules dendritiques ainsi que les medicaments et compositions pharmaceutiques contenant de tels polypeptides | |
| CN101374857A (zh) | 新的t辅助细胞抗原决定簇（thd）肽 | |
| RU2011147479A (ru) | Хелперный пептид ракового антигена | |
| AU2013205737A1 (en) | HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160310 |